Noah Allan Kolb1, Albert Gordon Smith2, John Robinson Singleton2, Susan L Beck3,4, Diantha Howard5, Kim Dittus6, Summer Karafiath2, Kathi Mooney3,4. 1. Department of Neuroscience, University of Vermont Medical Center, 1 South Prospect Street, MS 405AR2, Burlington, VT, 05401, USA. noah.kolb@uvmhealth.org. 2. Department of Neurology, University of Utah, Salt Lake City, UT, USA. 3. College of Nursing, University of Utah, Salt Lake City, UT, USA. 4. Huntsman Cancer Institute, Salt Lake City, UT, USA. 5. Clinical Research Center, University of Vermont, Burlington, VT, USA. 6. Department of Medicine, Hematology/Oncology, University of Vermont, Burlington, VT, USA.
Abstract
PURPOSE: The purpose of this study was to evaluate a new care model to reduce chemotherapy-induced neuropathic symptoms. Neuropathic symptom usual care was prospectively compared to an automated symptom-monitoring and coaching system, SymptomCare@Home (SCH), which included nurse practitioner follow-up triggered by moderate to severe symptoms. METHODS: Patients beginning chemotherapy were randomized to usual care (UC) or to the SCH intervention. This sub-analysis included only taxane/platin therapies. Participants called the automated telephone symptom-monitoring system daily to report numbness and tingling. The monitoring system recorded patient-reported neuropathic symptom severity, distress, and activity interference on a 0-10 scale. UC participants were instructed to call their oncologist for symptom management. SCH participants with symptom severity of ≥ 4 receivedautomated self-care strategies, and a nurse practitioner (NP) provided guideline-based care. RESULTS: There were 252 participants, 78.6% of which were female. Mean age was 55.1 years. Mean follow-up was 90.2 ± 39.9 days (81.1 ± 40.3 calls). SCH participants had fewer days of moderate (1.8 ± 4.0 vs. 8.6 ± 17.3, p < 0.001) and severe chemotherapy-induced peripheral neuropathy symptoms (0.3 ± 1.0 vs. 1.1 ± 5.2, p = 0.006). SCH participants had fewer days with moderate and severe symptom-related distress (1.4 ± 3.7 vs. 6.9 ± 15.0, p < 0.001; 0.2 ± 0.9 vs. 1.5 ± 6.1, p = 0.001) and trended towards less activity interference (3.3 ± 1.9 vs. 3.8 ± 2.1, p = 0.08). Other neuropathic symptoms were addressed in 5.8-15.4% of SCH follow-up calls. CONCLUSIONS: The SCH system effectively identified neuropathic symptoms and their severity and, paired with NP follow-up, reduced symptom prevalence, severity, and distress compared to usual care.
RCT Entities:
PURPOSE: The purpose of this study was to evaluate a new care model to reduce chemotherapy-induced neuropathic symptoms. Neuropathic symptom usual care was prospectively compared to an automated symptom-monitoring and coaching system, SymptomCare@Home (SCH), which included nurse practitioner follow-up triggered by moderate to severe symptoms. METHODS:Patients beginning chemotherapy were randomized to usual care (UC) or to the SCH intervention. This sub-analysis included only taxane/platin therapies. Participants called the automated telephone symptom-monitoring system daily to report numbness and tingling. The monitoring system recorded patient-reported neuropathic symptom severity, distress, and activity interference on a 0-10 scale. UC participants were instructed to call their oncologist for symptom management. SCHparticipants with symptom severity of ≥ 4 received automated self-care strategies, and a nurse practitioner (NP) provided guideline-based care. RESULTS: There were 252 participants, 78.6% of which were female. Mean age was 55.1 years. Mean follow-up was 90.2 ± 39.9 days (81.1 ± 40.3 calls). SCHparticipants had fewer days of moderate (1.8 ± 4.0 vs. 8.6 ± 17.3, p < 0.001) and severe chemotherapy-induced peripheral neuropathy symptoms (0.3 ± 1.0 vs. 1.1 ± 5.2, p = 0.006). SCHparticipants had fewer days with moderate and severe symptom-related distress (1.4 ± 3.7 vs. 6.9 ± 15.0, p < 0.001; 0.2 ± 0.9 vs. 1.5 ± 6.1, p = 0.001) and trended towards less activity interference (3.3 ± 1.9 vs. 3.8 ± 2.1, p = 0.08). Other neuropathic symptoms were addressed in 5.8-15.4% of SCH follow-up calls. CONCLUSIONS: The SCH system effectively identified neuropathic symptoms and their severity and, paired with NP follow-up, reduced symptom prevalence, severity, and distress compared to usual care.
Authors: Cindy Tofthagen; Kristine A Donovan; Mary Ann Morgan; David Shibata; Yating Yeh Journal: Support Care Cancer Date: 2013-08-01 Impact factor: 3.603
Authors: J S Gewandter; L Fan; A Magnuson; K Mustian; L Peppone; C Heckler; J Hopkins; M Tejani; G R Morrow; S G Mohile Journal: Support Care Cancer Date: 2013-02-28 Impact factor: 3.603
Authors: Janet H Van Cleave; Mei R Fu; Antonia V Bennett; Catherine Concert; Ann Riccobene; Anh Tran; Allison Most; Maria Kamberi; Jacqueline Mojica; Justin Savitski; Elise Kusche; Mark S Persky; Zujun Li; Adam S Jacobson; Kenneth S Hu; Michael J Persky; Eva Liang; Patricia M Corby; Brian L Egleston Journal: Mhealth Date: 2021-01-20
Authors: César Cuevas-Lara; Mikel Izquierdo; Fabiola Zambom-Ferraresi; Mikel L Sáez de Asteasu; Itxaso Marín-Epelde; Chenhui Chenhuichen; Fabricio Zambom-Ferraresi; Robinson Ramírez-Vélez; Antonio García-Hermoso; Álvaro Casas-Herrero; Amaya Capón-Sáez; Lucia Lozano-Vicario; Irene Criado-Martín; Marina Sánchez-Latorre; Cristina Antoñanzas-Valencia; Nicolás Martínez-Velilla Journal: Int J Environ Res Public Health Date: 2020-11-01 Impact factor: 3.390
Authors: M Aapro; P Bossi; A Dasari; L Fallowfield; P Gascón; M Geller; K Jordan; J Kim; K Martin; S Porzig Journal: Support Care Cancer Date: 2020-06-12 Impact factor: 3.603
Authors: Grant A Wintheiser; Kathryn J Ruddy; Jeph Herrin; Parvez A Rahman; Deirdre R Pachman; Aaron L Leppin; Lila J Finney Rutten; Minji K Lee; Joan M Griffin; Cindy Tofthagen; Linda L Chlan; Jennifer L Ridgeway; Sandra A Mitchell; Andrea L Cheville Journal: J Natl Cancer Inst Date: 2022-03-08 Impact factor: 13.506